Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Digital PCR-based T Cell Quantification Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange M, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GP, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Aug 9. pii: molcanres.0114.2018. doi: 10.1158/1541-7786.MCR-18-0114. [Epub ahead of print]

PMID:
30093564
2.

GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.

Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, Out-Luiting JJ, Bergman W, Verdijk RM, Jager MJ, van der Velden PA.

Br J Cancer. 2017 Sep 5;117(6):884-887. doi: 10.1038/bjc.2017.259. Epub 2017 Aug 15.

PMID:
28809862
3.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

4.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

5.

Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays.

Zoutman WH, Nell RJ, Versluis M, van Steenderen D, Lalai RN, Out-Luiting JJ, de Lange MJ, Vermeer MH, Langerak AW, van der Velden PA.

J Mol Diagn. 2017 Mar;19(2):236-243. doi: 10.1016/j.jmoldx.2016.10.006. Epub 2016 Dec 22.

PMID:
28012713
6.

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes.

van Essen TH, van Pelt SI, Bronkhorst IH, Versluis M, Némati F, Laurent C, Luyten GP, van Hall T, van den Elsen PJ, van der Velden PA, Decaudin D, Jager MJ.

PLoS One. 2016 Oct 20;11(10):e0164292. doi: 10.1371/journal.pone.0164292. eCollection 2016.

7.

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Cao J, Heijkants RC, Jochemsen AG, Dogrusöz M, de Lange MJ, van der Velden PA, van der Burg SH, Jager MJ, Verdijk RM.

Oncotarget. 2016 Jul 22;8(35):58021-58036. doi: 10.18632/oncotarget.10770. eCollection 2017 Aug 29.

8.

Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.

van der Ent W, Burrello C, de Lange MJ, van der Velden PA, Jochemsen AG, Jager MJ, Snaar-Jagalska BE.

Ocul Oncol Pathol. 2015 Apr;1(3):170-81. doi: 10.1159/000370159. Epub 2015 Apr 9. Review.

9.

Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.

van Dijk EH, Duits DE, Versluis M, Luyten GP, Bergen AA, Kapiteijn EW, de Lange MJ, Boon CJ, van der Velden PA.

Medicine (Baltimore). 2016 May;95(18):e3457. doi: 10.1097/MD.0000000000003457.

10.

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW.

Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071.

11.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

12.

Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.

de Lange MJ, Razzaq L, Versluis M, Verlinde S, Dogrusöz M, Böhringer S, Marinkovic M, Luyten GP, de Keizer RJ, de Gruijl FR, Jager MJ, van der Velden PA.

PLoS One. 2015 Sep 14;10(9):e0138002. doi: 10.1371/journal.pone.0138002. eCollection 2015.

13.

EMT-associated factors promote invasive properties of uveal melanoma cells.

Asnaghi L, Gezgin G, Tripathy A, Handa JT, Merbs SL, van der Velden PA, Jager MJ, Harbour JW, Eberhart CG.

Mol Vis. 2015 Aug 25;21:919-29. eCollection 2015.

14.

Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.

Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, Jager MJ, Luyten GP, van der Velden PA.

PLoS One. 2015 Mar 12;10(3):e0116371. doi: 10.1371/journal.pone.0116371. eCollection 2015.

15.

Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.

Herlihy N, Dogrusöz M, van Essen TH, Harbour JW, van der Velden PA, van Eggermond MC, Haasnoot GW, van den Elsen PJ, Jager MJ.

Invest Ophthalmol Vis Sci. 2015 Jan 15;56(3):1447-58. doi: 10.1167/iovs.14-15250.

16.

Modeling of human uveal melanoma in zebrafish xenograft embryos.

van der Ent W, Burrello C, Teunisse AF, Ksander BR, van der Velden PA, Jager MJ, Jochemsen AG, Snaar-Jagalska BE.

Invest Ophthalmol Vis Sci. 2014 Sep 23;55(10):6612-22. doi: 10.1167/iovs.14-15202.

PMID:
25249605
17.

Prognostic parameters in uveal melanoma and their association with BAP1 expression.

van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ.

Br J Ophthalmol. 2014 Dec;98(12):1738-43. doi: 10.1136/bjophthalmol-2014-305047. Epub 2014 Aug 21.

18.

Inhibition of CSF-1R supports T-cell mediated melanoma therapy.

Sluijter M, van der Sluis TC, van der Velden PA, Versluis M, West BL, van der Burg SH, van Hall T.

PLoS One. 2014 Aug 11;9(8):e104230. doi: 10.1371/journal.pone.0104230. eCollection 2014.

19.

Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma.

Bronkhorst IH, Jehs TM, Dijkgraaf EM, Luyten GP, van der Velden PA, van der Burg SH, Jager MJ.

JAMA Ophthalmol. 2014 May;132(5):614-21.

PMID:
24626595
20.

Mrassf1a-pap, a novel methylation-based assay for the detection of cell-free fetal DNA in maternal plasma.

van den Oever JM, Balkassmi S, Segboer T, Verweij EJ, van der Velden PA, Oepkes D, Bakker E, Boon EM.

PLoS One. 2013 Dec 31;8(12):e84051. doi: 10.1371/journal.pone.0084051. eCollection 2013.

21.

Bevacizumab and intraocular tumors: an intriguing paradox.

el Filali M, Ly LV, Luyten GP, Versluis M, Grossniklaus HE, van der Velden PA, Jager MJ.

Mol Vis. 2012;18:2454-67. Epub 2012 Oct 5.

22.

Anti-angiogenic therapy in uveal melanoma.

el Filali M, van der Velden PA, Luyten GP, Jager MJ.

Dev Ophthalmol. 2012;49:117-36. doi: 10.1159/000329591. Epub 2011 Oct 21. Review.

PMID:
22042017
23.

Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.

Mohseny AB, Tieken C, van der Velden PA, Szuhai K, de Andrea C, Hogendoorn PC, Cleton-Jansen AM.

Genes Chromosomes Cancer. 2010 Dec;49(12):1095-103. doi: 10.1002/gcc.20817.

PMID:
20737480
24.

In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages.

Ly LV, Baghat A, Versluis M, Jordanova ES, Luyten GP, van Rooijen N, van Hall T, van der Velden PA, Jager MJ.

J Immunol. 2010 Sep 15;185(6):3481-8. doi: 10.4049/jimmunol.0903479. Epub 2010 Aug 16.

25.

Regulation of VEGF-A in uveal melanoma.

el Filali M, Missotten GS, Maat W, Ly LV, Luyten GP, van der Velden PA, Jager MJ.

Invest Ophthalmol Vis Sci. 2010 May;51(5):2329-37. doi: 10.1167/iovs.09-4739. Epub 2009 Dec 30.

PMID:
20042655
26.

Episodic Src activation in uveal melanoma revealed by kinase activity profiling.

Maat W, el Filali M, Dirks-Mulder A, Luyten GP, Gruis NA, Desjardins L, Boender P, Jager MJ, van der Velden PA.

Br J Cancer. 2009 Jul 21;101(2):312-9. doi: 10.1038/sj.bjc.6605172. Epub 2009 Jun 30.

27.

Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

El Filali M, Homminga I, Maat W, van der Velden PA, Jager MJ.

Mol Vis. 2008 Sep 24;14:1752-9.

28.

Methylation in uveal melanoma.

van der Velden PA, Maat W.

Br J Ophthalmol. 2009 Jan;93(1):132. doi: 10.1136/bjo.2008.144238. Epub 2008 Jul 23. No abstract available.

PMID:
18650211
29.

Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.

Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA.

Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1291-8. doi: 10.1167/iovs.07-1135.

PMID:
18385040
30.

Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.

Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, Van der Velden PA.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):23-7. doi: 10.1167/iovs.07-0722.

PMID:
18172070
31.

Epigenetic inactivation of RASSF1a in uveal melanoma.

Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ, Gruis NA.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):486-90.

PMID:
17251440
32.

Aberrant DNA methylation in cutaneous malignancies.

van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP.

Semin Oncol. 2005 Oct;32(5):479-87. Review.

PMID:
16210089
33.

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.

van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH, Tensen CP.

J Clin Oncol. 2005 Jun 10;23(17):3886-96. Epub 2005 May 16.

PMID:
15897551
34.

Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress.

Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA, de Heer E, Hiemstra PS, Poorthuis BJ, Walther FJ.

Free Radic Biol Med. 2004 Mar 15;36(6):782-801.

PMID:
14990357
35.

Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development.

Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, Frants RR, Jager MJ, Gruis NA.

Br J Cancer. 2003 Nov 17;89(10):1914-9.

36.

Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.

van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, Frants RR, Tensen CP, Willemze R, Jager MJ, Gruis NA.

Int J Cancer. 2003 Sep 10;106(4):472-9. Erratum in: Int J Cancer. 2004 Oct 10;111(6):982.

37.

Homozygous germline mutation of CDKN2A/p16 and glucose-6-phosphate dehydrogenase deficiency in a multiple melanoma case.

Pavel S, Smit NP, van der Meulen H, Kolb RM, de Groot AJ, van der Velden PA, Gruis NA, Bergman W.

Melanoma Res. 2003 Apr;13(2):171-8.

PMID:
12690301
38.

Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma.

van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA.

Am J Hum Genet. 2001 Oct;69(4):774-9. Epub 2001 Aug 7.

39.

Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.

van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ.

Cancer Res. 2001 Jul 1;61(13):5303-6.

40.

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).

Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W.

Int J Cancer. 2000 Sep 15;87(6):809-11.

41.

Familial melanoma; CDKN2A and beyond.

Gruis NA, van der Velden PA, Bergman W, Frants RR.

J Investig Dermatol Symp Proc. 1999 Sep;4(1):50-4. Review.

42.

A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.

van der Velden PA, Sandkuijl LA, Bergman W, Hille ET, Frants RR, Gruis NA.

Genome Res. 1999 Jun;9(6):575-80.

43.

Genetics of familial atypical multiple mole-melanoma (FAMMM) syndrome in The Netherlands: how far have we come?

Gruis NA, Van der Velden PA, Bergman W, Frants RR.

Bull Cancer. 1998 Jul;85(7):627-30.

44.

Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations.

Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK.

Hum Mutat. 1998;11(6):424-31.

PMID:
9603434
45.

Use of the direct RNA amplification technique NASBA to detect factor V Leiden, a point mutation associated with APC resistance.

Reitsma PH, van der Velden PA, Vogels E, van Strijp D, Tacken N, Adriaansen H, van Gemen B.

Blood Coagul Fibrinolysis. 1996 Sep;7(6):659-63.

PMID:
8899156
46.

Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds.

Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR.

Nat Genet. 1995 Jul;10(3):351-3.

PMID:
7670475
47.

CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families.

Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR.

Melanoma Res. 1995 Jun;5(3):169-77.

PMID:
7640518
48.

Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS).

Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP.

Thromb Haemost. 1994 Jun;71(6):719-22.

PMID:
7974338
49.

Mutation in blood coagulation factor V associated with resistance to activated protein C.

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH.

Nature. 1994 May 5;369(6475):64-7.

PMID:
8164741
50.

Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40.

Eikenboom JC, Reitsma PH, van der Velden PA, Briët E.

Br J Haematol. 1993 Jul;84(3):533-5.

PMID:
8105872

Supplemental Content

Loading ...
Support Center